Day: October 17, 2024

WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) — HMP Partners and The Patel Family LLP, leading investors in innovative healthcare ventures, congratulate Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) and founding CEO Dr. Ryan Saadi for being honored with prestigious proclamation by the Township of Warren, New Jersey, in recognition of their Nobel Prize nomination for pioneering business model to alleviate health inequality through breakthrough life-saving medical innovations. Warren Township, New Jersey, Office of Mayor Victor J Sordillo, has recognized Tevogen Bio and its founding CEO, Ryan Saadi, MD, MPH, for their innovative business model aimed at addressing health inequality through the establishment of a multi-billion-dollar cell therapy biotech in Warren, NJ. On behalf of Warren Township, Mayor Sordillo...

Lead indication for ZyVersa’s Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications.WESTON, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a Letter to Shareholders highlighting obesity development plans for Inflammasome ASC Inhibitor IC 100 with anticipated milestones over the next nine months. The full text of the letter follows. A MESSAGE FROM OUR PRESIDENT AND CHIEF EXECUTIVE OFFICER To my fellow shareholders, As announced in late July, ZyVersa selected obesity with metabolic complications as the lead indication for...

NORCROSS, Ga., Oct. 17, 2024 (GLOBE NEWSWIRE) — CoreCard Corporation (NYSE: CCRD), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, intends to hold an investor conference call on October 31, 2024, at 11:00 A.M. Eastern Time in conjunction with the company’s earnings release for the quarter ended September 30, 2024. The company plans to issue a press release with the financial results for the period before the market opens on October 31, 2024. Interested investors are invited to attend the conference call by accessing the webcast at https://www.webcast-eqs.com/register/corecard103124/en   or by dialing 1-877-407-0890. As part of the conference call CoreCard will be conducting a question-and-answer session where participants are invited to email...

ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy Presentation scheduled for 3:15 pm ET on October 17, 2024 HALIFAX, Nova Scotia, Oct. 17, 2024 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that Gary Nabors, Ph.D., Chief Development Officer, and key members of Appili’s scientific team, will participate at IDWeek 2024™, and present an update on the Appili biodefense program ATI-1701. The conference is being held from October 16-19 2024, at the Los Angeles Convention Center. The poster presentation will provide...

Advancements in drone technology to be presented at the leading aviation industry event, fostering cross-industry collaboration. Saskatoon, Sask., Oct. 17, 2024 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading developer of drone solutions and systems, proudly announces its participation in the upcoming Wings of Saskatchewan event in Regina, from October 30 to October 31, 2024. Draganfly will showcase its latest drone technology advancements, contributing to discussions on industry trends, safety, and regulatory considerations alongside key stakeholders in the aviation sector. The Wings of Saskatchewan Conference, hosted by the Saskatchewan Aerial Applicators Association and the Saskatchewan Aviation Council, serves as a vital gathering for...

Hypha Labs’ Micro Pearls™ Could be to Mushrooms What Keurig is to Coffee An Emerging Markets Sponsored Commentary ORLANDO, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) — Today’s featured profile ticks all the boxes for us when we are looking at a potential investment . It is a potential monster in the exploding mushroom industry with proprietary game-changer technology and a compelling path to market. We believe potential for enormous sales in a direct-to-consumer market and in commercial kitchens is highly compelling. Let’s get right to the point. Hypha Labs (OTCQB: FUNI) has INVENTED both a home and commercial device to produce top notch functional mushroom ingredients in eight days or so using a compact device that easily sits on a countertop. That means Mom or Dad can take the proprietary solution for the functional mushroom...

OTTAWA, Ontario, Oct. 17, 2024 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX: CGY), closed fiscal year 2024 ending September 30, having signed several defence contracts in the fourth quarter valued at approximately $29 million, further solidifying its position as a trusted partner in the global defence industry. These new contracts align with Calian’s mission to equip, prepare and protect military personnel as global military spending continues to surge amid war, geopolitical instability and the heightened need for new and advanced technologies. Global defence budgets continue to rise and are projected to reach $2.5 trillion by 2028 according to Markets and Markets. Throughout FY2024, Calian continued to win contracts to support key global defence initiatives that enhance military readiness and operational effectiveness. Closing out...